Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2020-02, Vol.156 (2), p.488-497
Main Authors: Veneris, Jennifer Taylor, Matulonis, Ursula A., Liu, Joyce F., Konstantinopoulos, Panagiotis A.
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
BRCA1 Protein - genetics
BRCA2 Protein - genetics
Developmental therapeutics
DNA damage repair
DNA Repair
Female
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Humans
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - immunology
PARP inhibitors
Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage
Randomized Controlled Trials as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations. •PARP inhibitors (PARPi) have transformed the management of advanced ovarian cancer.•With increased PARPi use, the resistance to PARPi will become a increasing clinical concern.•Combinatorial approaches can overcome de novo and acquired resistance to PARPi by exploiting DDR mechanisms.•PARPi combinations can induce “BRCAness”, inhibit DNA repair, promote replication stress, or enhance immunomodulation.•Selection of the appropriate combination for the clinical context could overcome, or prevent, PARPi resistance.
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2019.09.021